Arcus Biosciences advances casdatifan combinations, reports $775M cash at midyear 2026
Arcus added three new clinical collaborations for its HIF-2α inhibitor casdatifan and said cash runway extends to at least the second half of 2028.
Arcus Biosciences reported second-quarter 2026 results on August 5, 2026, with a focus on expanding its development strategy for casdatifan, a HIF-2α inhibitor in clear cell renal cell carcinoma (ccRCC).
The company announced three new clinical collaborations. Bristol Myers Squibb will add casdatifan combinations as two new arms of its Phase 1/2 ROSETTA RCC-208 study, evaluating casdatifan with the anti-PD-L1/VEGF-A bispecific antibody pumitamig, jointly developed by BioNTech and BMS.1 Summit Therapeutics will add a new ARC-20 cohort testing casdatifan with the PD-1/VEGF bispecific antibody ivonescimab in first-line ccRCC.1 AVEO Oncology will support a new ARC-20 cohort evaluating casdatifan with the VEGFR TKI tivozanib in patients previously treated with belzutifan.1 Arcus also disclosed a fourth agreement with an undisclosed partner testing casdatifan alongside another anti-PD-x/VEGF bispecific antibody in first-line ccRCC, which is expected to initiate in the fourth quarter of 2026.1
On regulatory and trial timing, the ARC-20 cohort testing casdatifan plus zimberelimab and ipilimumab is enrolling to support the Phase 3 PEAK-20 trial of casdatifan plus nivolumab plus ipilimumab, expected to start by year-end 2026.1 Enrollment in the Phase 3 PEAK-1 trial of casdatifan plus cabozantinib versus cabozantinib alone is accelerating, with completion still expected by year-end 2026.1
The European Medicines Agency granted orphan drug designation in May 2026 to quemliclustat for pancreatic cancer, following similar U.S. FDA designation in June 2025.1
On the anti-TIGIT program, Arcus and AstraZeneca will discontinue the Phase 3 PACIFIC-8 study of domvanalimab plus durvalumab in NSCLC, following earlier discontinuations of the STAR-221 and STAR-121 studies with Gilead.1 Gilead has relinquished its three board seats effective August 5, 2026.1
Cash, cash equivalents and marketable securities were $775 million as of June 30, 2026, down from $1.0 billion at year-end 2025, with the company stating this is sufficient to fund operations until at least the second half of 2028.1 Arcus expects to end 2026 with approximately $600 million in cash.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.